Vetoquinol is launching Cimalgex, a new NSAID for dogs this month.

Cimalgex (cimicoxib) is a new second generation COX-2 inhibitor which can be used for the treatment of pain and inflammation due to osteoarthritis and the management of peri-operative pain associated with orthopaedic and soft tissue surgery, for which it can be given two hours before surgery and continued for 3-7 days post surgery.

Vetoquinol says that an important consideration in treating dogs with osteoarthritis, many of which are geriatric, is that there are no contraindications to using Cimalgex in patients with mild to moderate renal impairment.

According to the company, field trials showed that over 90 per cent of per owners and vets identified that animals experienced excellent analgesia post operatively*.

Available in a chewable, splitable tablet, Cimalgex can be given with or without food.

Vetoquinol says that the excellent tolerability, efficacy profile and ease of use of Cimalgex means that veterinary patients could benefit from pain relief in situations where clinicians are worried about the risks versus the benefits of prescribing a NSAID for pain management.

Further information about assessing pain and decision making when it comes to prescribing NSAIDs, will be presented in a free webinar on 19th October at 8.30pm. To register go to www.thewebinarvet.com/vetoquinol and enter code CIM1.

Reference
*E. Grandemange: Field evaluation of the efficacy and the safety of cimicoxib in the relief of peri-operative pain in dogs; 2008, study number n°3008C2F1

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.